MyFinsight
Home
About
Contact
inva: the income statement
Download
Download image
Long Acting
Beta2Agonist Anoro
$11,844K
Long Acting
Beta2Agonist Relvar Breo
$51,508K
ZEVTERA
$113K
Xerava
$4,909K
Xacduro
$23,813K
Giapreza
$18,459K
Total royalties
$63,352K
License And Other
Revenue
$610K
Product
$47,294K
Royalty
$59,896K
Less amortization of
capitalized fees paid
$3,456K
Total revenue
$107,800K
(20.44%↑ Y/Y)
Gross profit
$75,539K
Amortization of acquired
intangible assets
$6,618K
Cost of products sold
(inclusive of amortization...
$25,643K
Interest and dividend
income
$5,472K
(-0.51%↓ Y/Y)
Changes in fair values of
equity and long-term...
$31,510K
(286.05%↑ Y/Y)
Changes in fair values of
equity method...
$30,751K
(268.67%↑ Y/Y)
Income from operations
$34,578K
Total operating
expenses
$40,961K
Income before income
taxes
$97,817K
(1328.19%↑ Y/Y)
Other expense, net
-$479K
(47.59%↑ Y/Y)
Interest expense
$4,015K
(-30.86%↓ Y/Y)
Research and development
$13,670K
(284.96%↑ Y/Y)
Selling, general and
administrative
$27,291K
(4.09%↑ Y/Y)
Net income and
comprehensive income
$89,908K
(7312.04%↑ Y/Y)
Income tax expense, net
$7,909K
(40.33%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Innoviva, Inc. (INVA)
Innoviva, Inc. (INVA)